EM
Therapeutic Areas
Mapi Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Glatiramer Acetate Depot | Relapsing‑remitting Multiple Sclerosis | Phase 3 |
| Pregabalin ER | Neuropathic Pain / Epilepsy | Preclinical |
| GLP‑1 Peptide Long‑Acting Injectable | Metabolic Disease | Preclinical |
| Buspirone ER | Anxiety | Preclinical |
| Paliperidone Depot | Schizophrenia | Preclinical |
| Aripiprazole Depot | Schizophrenia | Preclinical |
Leadership Team at Mapi Pharma
UD
Uri Danon
Executive VP
IZ
Irit Zalayet
VP Finance
SR
Shai Rubnov, Ph.D.
VP R&D
AM
Alex Mogle
VP Corporate Development
LP
Laura Popper, M.D.
VP Clinical Development
NB
Nadav Bleich Kimelman, DMD, Ph.D.
VP Pharmaceutical Development
OM
Oren Milani
Head of Quality